Business
2025 AACR | Abbisko Therapeutics Presents Late-Breaking Pre-clinical Research Results on ABSK112 (EGFR exon20ins), ABSK131 (PRMT5*MTA), and ABK-KRAS-1
Abbisko Therapeutics Co., Ltd. (Abbisko Therapeutics 02256.HK) today announced that it has presented four late-breaking pre-clinical research posters at the 2025 AACR conference held in Chicago, Illinois (USA) from April 25 to April 30. Results were shared for ABSK112 (EGFR exon20ins inhibitor), ABSK131 (PRMT5*MTA inhibitor), and ABK-KRAS-1 (pan-KRAS inhibitor), as well as results from a study investigating potential resistance mechanisms to KRAS G12C inhibitors.
About this update from Abbisko Cayman Limited
[{"type":"text","content":"SHANGHAI, April 27, 2025 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. (Abbisko Therapeutics 02256.HK) today announced that it has presented four late-breaking pre-clinical research posters at the 2025 AACR conference held in Chicago, Illinois (USA) from April 25 to April 30. Results were shared for ABSK112 (EGFR exon20ins inhibitor), ABSK131 (PRMT5*MTA inhibitor), and ABK-KRAS-1 (pan-KRAS inhibitor), as well as results from a study investigating potential resistance mechanisms to KRAS G12C inhibitors.","length":518,"tagName":"p"},{"type":"text","content":"Abbisko presented the following posters at the 2025 AACR:","length":57,"tagName":"p"},{"type":"text","content":"Title1: Preclinical Evaluation of ABSK112, a Selective and CNS-penetrant Compound with Strong HER2 Inhibitory Activity for Treating HER2-Driven Solid Tumors","length":156,"tagName":"p"},{"type":"text","content":"Session Category: Late-Breaking Research: Experimental and Molecular Therapeutics 2","length":83,"tagName":"p"},{"type":"text","content":"Session Date and Time: April 28, 2025, 2:00 PM - 5:00 PM (CDT)","length":62,"tagName":"p"},{"type":"text","content":"Location: Poster Section 54","length":32,"tagName":"p"},{"type":"text","content":"Poster Board Number: 14","length":23,"tagName":"p"},{"type":"text","content":"Poster Number: LB240","length":20,"tagName":"p"},{"type":"text","content":"Conclusion:","length":11,"tagName":"p"},{"type":"text","content":"Our findings establish ABSK112 as a potent, selective and CNS-penetrant HER2 inhibitor, warranting further clinical evaluation of it as a monotherapy or in combination with HER2-targeted ADCs for the treatment of HER2+ cancers with brain metastases.","length":249,"tagName":"p"},{"type":"text","content":"Title 2: Loss-of-Function (LoF) of KEAP1 promotes cell survival through multiple mechanisms, leading to resistance to KRAS G12C inhibitors","length":138,"tagName":"p"},{"type":"text","content":"Session Title: Late-Breaking Research: Experimental and Molecular Therapeutics 3","length":80,"tagName":"p"},{"type":"text","content":"Session Date and Time: April 29, 2025 9: 00AM – 12: 00 PM (CDT)","length":68,"tagName":"p"},{"type":"text","content":"Location: Poster Section 52","length":32,"tagName":"p"},{"type":"text","content":"Poster Board Number: 1","length":22,"tagName":"p"},{"type":"text","...